VICTORIA HEGLAR: Open Payments
NPI 1407468515 · COSTA MESA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,133 in 89 payments from 17 companies in 2025. Trend: 2023 $22 · 2024 $219 · 2025 $2,133
Food & beverage: $2,133
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 11 | $282 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $275 |
| ABBVIE INC. | 9 | $208 |
| Vanda Pharmaceuticals Inc. | 8 | $208 |
| Alkermes, Inc. | 5 | $204 |
| Otsuka America Pharmaceutical, Inc. | 7 | $188 |
| Teva Pharmaceuticals USA, Inc. | 13 | $180 |
| Janssen Pharmaceuticals, Inc | 7 | $176 |
| Axsome Therapeutics, Inc. | 3 | $81 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $65 |
Products named: INGREZZA, CAPLYTA, VRAYLAR, FANAPT, ARISTADA, AUSTEDO XR, REXULTI, SPRAVATO.
Industry payments across CA — which companies pay providers there.
